Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors.
Journal: Journal of medicinal chemistry
Published: December 06, 2024
Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
Journal: Breast cancer research and treatment
Published: May 11, 2023
I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer.
Journal: Current breast cancer reports
Published: December 14, 2020
Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: July 29, 2020
Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis.
Journal: Breast cancer (Tokyo, Japan)
Published: July 20, 2020
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Journal: Bioorganic & medicinal chemistry letters
Published: June 16, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: May 12, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Journal: Science translational medicine
Published: August 24, 2019
Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension.
Journal: British journal of pharmacology
Published: May 26, 2017
Last Updated: 09/26/2026